NASDAQ
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks ...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $0.65 per share a year ago....
Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company...
Avidity is at the forefront of an exciting new class of treatments. Avidity shareholders will receive consideration for an exciting spinoff before Novartis acquires Avidity....
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, Pfizer, Incyte, AbbVie, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock ...
UnitedHealth Group, Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener ...
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
No price data available for this timeframe.